Canaccord Genuity initiated coverage on Exagen with a new price target
$XGN
Medical Specialities
Health Care
Canaccord Genuity initiated coverage of Exagen with a rating of Buy and set a new price target of $25.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2025 | $12.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 7/23/2025 | $12.00 | Buy | Craig Hallum |
| 8/5/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/11/2021 | $33.00 → $30.00 | Overweight | Keybanc |
| 10/15/2021 | $26.00 | Outperform | Cowen |
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
SCHEDULE 13G/A - EXAGEN INC. (0001274737) (Subject)
10-Q - EXAGEN INC. (0001274737) (Filer)
8-K - EXAGEN INC. (0001274737) (Filer)
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: Wednesday, September 3, 2025 Location: Marriott Marquis Hotel in NY, NY About Exagen Exagen Inc. (NASDAQ:XGN) is a leading provider of autoimmune diagnost
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 (Unaudited, in thousands, exceptASP data) Revenue $17,202 $15,064 $32,700 $29,479 Gross margin 60.4% 60.1% 59.7% 59.9%Operating expenses $13,025 $11,643 $25,513 $23,244 Operating loss $(2,630) $(2,587) $(5,995) $(5,590) Net loss $(4,439) $(2,966) $(8,191) $(6,326) Adjusted EBITDA $(1,721) $(1,598) $(4,229) $(3,590) Cash and cash equivalents $30,033 $24,479 $30
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde
KeyBanc Capital Markets upgraded Exagen from Sector Weight to Overweight and set a new price target of $12.00
Craig Hallum initiated coverage of Exagen with a rating of Buy and set a new price target of $12.00
KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight
4/A - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exa
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. Three Months Ended March 31, 2025 2024 (in thousands, except ASP data) Revenue $15,498 $14,415 Gross margin 58.9% 59.6%Operating expenses $12,488 $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194 $27,267 Trailing-twelve-month average selling price (ASP) $419 $377 Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci